Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

20.37 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1
Open	20.37
Bid (Size)	19.99 (100)
Ask (Size)	21.50 (400)
Prev. Close	20.37
Today's Range	20.37 - 20.37
52wk Range	8.672 - 22.88
Shares Outstanding	14,828,456
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Anika (ANIK) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Revenue hit $32.6 million with record commercial channel sales and expanded margins.

Via The Motley Fool

Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One

August 04, 2026

Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)

From American News Group

Via GlobeNewswire

Performance

YTD	+117.9%	+117.9%
1 Month	-3.5%	-3.5%
3 Month	+35.7%	+35.7%
6 Month	+44.2%	+44.2%
1 Year	+122.9%	+122.9%

More News

Anika Therapeutics Q2 Earnings Call Highlights ↗

July 29, 2026

Via MarketBeat

Anika Therapeutics (NASDAQ:ANIK) Soars on Q2 Earnings Beat, Revenue and EPS Top Estimates ↗

July 29, 2026

Via Chartmill

Anika Therapeutics Inc (NASDAQ:ANIK) Soars on Q1 Earnings and Revenue Beat ↗

April 29, 2026

Via Chartmill

ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Delivers Decisive Q4 2025 Earnings Beat, Sparking Share Rally ↗

February 26, 2026

Via Chartmill

Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026

July 15, 2026

From Anika Therapeutics Inc.

Via GlobeNewswire

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2026

From Anika Therapeutics Inc.

Via GlobeNewswire

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

April 30, 2026

From TELA Bio, Inc.

Via GlobeNewswire

Anika (ANIK) Q1 2026 Earnings Transcript ↗

April 29, 2026

Via The Motley Fool

Anika (ANIK) Q2 2025 Earnings Call Transcript ↗

April 21, 2026

Via The Motley Fool

Anika (ANIK) Q4 2025 Earnings Call Transcript ↗

April 21, 2026

Via The Motley Fool

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026

April 15, 2026

From Anika Therapeutics Inc.

Via GlobeNewswire

Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens

April 13, 2026

Via MarketMinute

Telix Strengthens Board with Additional Director Appointments

April 08, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2026

From Anika Therapeutics Inc.

Via GlobeNewswire

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference

February 18, 2026

From Anika Therapeutics Inc.

Via GlobeNewswire

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

February 12, 2026

From Anika Therapeutics Inc.

Via GlobeNewswire

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

January 26, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.

January 23, 2026

From Kirby McInerney LLP

Via Business Wire

Anika Therapeutics Announces Leadership Transition

January 08, 2026

From Anika Therapeutics Inc.

Via GlobeNewswire

ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP

December 30, 2025

From Kirby McInerney LLP

Via Business Wire

Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK

December 05, 2025

From Kirby McInerney LLP

Via GlobeNewswire

Anika (ANIK) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Via The Motley Fool

Frequently Asked Questions

Is Anika Therapeutics Inc. - Common Stock publicly traded?

Yes, Anika Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Anika Therapeutics Inc. - Common Stock trade on?

Anika Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Anika Therapeutics Inc. - Common Stock?

The ticker symbol for Anika Therapeutics Inc. - Common Stock is ANIK on the Nasdaq Stock Market

What is the current price of Anika Therapeutics Inc. - Common Stock?

The current price of Anika Therapeutics Inc. - Common Stock is 20.37

When was Anika Therapeutics Inc. - Common Stock last traded?

The last trade of Anika Therapeutics Inc. - Common Stock was at 09/25/26 04:00 PM ET

What is the market capitalization of Anika Therapeutics Inc. - Common Stock?

The market capitalization of Anika Therapeutics Inc. - Common Stock is 302.06M

How many shares of Anika Therapeutics Inc. - Common Stock are outstanding?

Anika Therapeutics Inc. - Common Stock has 302M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.